Search
gemifloxacin (Factive)
Tradename: Factive (FDA approved 2003)
Indications:
- bacterial infections due to susceptible organisms
- acute bronchitis or exacerbation
- community-acquired pneumonia, including multidrug-resistant Streptococcus pneumonia
Contraindications:
- NOT for use in urinary tract infections does not reach adequate concentrations in urine
Dosage: PO QD dosing, with or without meals
Antimicrobial activity:
- Streptococcus pneumonia
- Klebsiella pneumoniae
- Mycoplasma pneumoniae
- Chlamydophila pneumoniae
- Haemophilus influenzae
- Moraxella catarrhalis
Adverse effects:
-> rash, maculopapular, non pruritic (3%) [2]
a) more likely than other fluoroquinolones to cause rash
b) more likely if therapy > 7 days
c) more common in patients < 40 years of age & postmenopausal women on hormone replacement therapy
Drug interactions:
-> Al+3 or Mg+2-containing antiacids, Fe+2, multivitamins with minerals, sucralfate, Videx interfere with absorption; separate by 2-3 hours
Mechanism of action:
-> fluoroquinolone
Interactions
drug interactions
drug adverse effects of fluoroquinolones
General
fluoroquinolone
Properties
INHIBITS: DNA gyrase
Database Correlations
PUBCHEM correlations
References
- Prescriber's Letter 11(2):suppl 2004 {GeneSoft}
- Prescriber's Letter 11(9): 2004
Summary of Commonly Used Fluoroquinolones
Detail-Document#: 200906
(subscription needed) http://www.prescribersletter.com
- Deprecated Reference